Our investigation showed that PP2A activation using a SMAP compound (DT-061) (21) induced marked cytotoxicity in leukemia cell lines or patient-derived CLL cells that exhibited antiapoptotic multidrug resistance. The gene discussed is PTPA; the disease is B-cell chronic lymphocytic leukemia.